Search results for: 'modality sensor'

The bio‑CDMO industry is entering an era of accelerated growth driven by the global shift toward complex biologics, including monoclonal antibodies, antibody-drug conjugates (ADCs), cell and gene therapies, recombinant proteins, and advanced vaccines. Large molecules are projected to record a 10.3% CAGR between 2025 and 2031, signaling sustained de...

There have been increasing incidences of rare ophthalmic diseases (e.g., retinitis pigmentosa, Stargardt disease, Leber congenital amaurosis) and prevalent diseases (e.g., age-related macular degeneration [AMD], geographic atrophy). While clinicians have used small molecules as the conventional therapeutic modality to manage these diseases, the urg...

Rare diseases pose a global burden to healthcare despite making up a very small fraction of the global disease landscape. Most treatment options for rare diseases focus on maintaining the disease symptoms, rather than a disease-modifying approach. To address this unmet need, RNA therapies are emerging as disease-modifying approaches addressing the ...

Frost & Sullivan provides comprehensive insights into the global biologics contract development and manufacturing organization (bio-CDMO) market, including emerging trends, growth opportunities, and profiles of leading bio-CDMOs and their business model evolution. The growth of next-generation biologics and personalized therapies and the emergence ...

This research service provides a comprehensive analysis of the European molecular imaging market. This research service includes an analysis of the challenges affecting the industry, the factors driving and restraining the market growth and the opportunities that participants can look forward to during the forecast period (2012 to 2018). This study...

The global decentralized clinical trial (DCT) market has been witnessing a continued surge after the COVID-19 pandemic. The accelerated DCT adoption in 2020 was driven by restricted mobility of site investigators, clinical research associates, and patients to participate in trials, which resulted in a significant halt in trial activities worldwide....

This growth insight report presents an analysis of the technological and clinical disruptions that are set to impact the global medical imaging industry. The healthcare industry is undergoing rapid changes catalyzed by innovative technologies, and the impact on the imaging industry is likely to be quite significant. Though emerging technologies suc...

09 Oct 2024  |  North America  |  Technology Research

Innovations and Growth Opportunities in the Biopsy Industry, 2024 2028

Exploring Recent Developments and Emerging Opportunities in Solid Tissue Biopsy and Breath Biopsy Thanks to Advancements in Precision, Automation, and Connectivity

Infographics

×

The biopsy device market s landscape is transforming due to technological advancements, evolving clinical needs, and the push for greater precision and minimally invasive approaches. In that context, this Frost & Sullivan analysis provides a comprehensive overview of different biopsy devices, with its main focus being solid tissue biopsy. In ad...

This study analyzes the Brazilian medical imaging market from 2011 to 2017, focusing exclusively on computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound. The analyzed total market is expected to growth with a single-digit CAGR for 2012 to 2017. This growth rate is mainly driven by the C-class economic growth that allows increa...